Corvus Pharmaceuticals, Inc. reported first quarter ended March 31, 2026 results: net income Net loss for the three months ended March 31, 2026 was $13.7 million.
“Net loss for the three months ended March 31, 2026 was $13.7 million”
Corvus Pharmaceuticals, Inc. — fact timeline
Source-grounded facts extracted from Corvus Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Corvus Pharmaceuticals, Inc. entered into Amended and Restated Open Market Sale Agreement with Jefferies LLC valued at maximum aggregate offering price of up to $200,000,000 (effective 2026-03-13).
“On March 13, 2026, the Company entered into an Amended and Restated Open Market Sale Agreement SM (the “Amended Sales Agreement”), with Jefferies LLC (“Jefferies”), to sell shares of the Company’s common stock, par value $0.0001 per share (“Common Stock”), from time to time through Jefferies acting as sales agent, having a maximum aggregate offering price of up to $200,000,000.”
Richard van den Broek was appointed as Director at Corvus Pharmaceuticals, Inc..
“appointed Richard van den Broek to the Board.”
Corvus Pharmaceuticals, Inc. entered into Securities Purchase Agreement with the investors named therein, including the companys chief executive officer and certain of the companys existing institutional investors, including investors affiliated with certain of the companys directors (collectively, the Investors ) valued at combined offering price of $1.7312 (effective 2024-05-01).
“On May 1, 2024, Corvus Pharmaceuticals, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the investors named therein, including the Company’s chief executive officer and certain of the Company’s existing institutional investors, including investors affiliated with certain of the Company’s directors (collectively, the “Investors”).”
Corvus Pharmaceuticals, Inc. reported financial results for the first quarter ended March 31, 2024.
“Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the first quarter ended March 31, 2024.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.